“…Recently, numerous in vitro, in vivo, and clinical studies about coatings that mitigate implant response, i.e., coatings induced by bone’s immune system, have been reported [ 1 , 2 , 3 , 4 ]. Since the implantation procedure destroys part of the bones and surrounding tissues and often evokes an inflammatory reaction, thus limiting the implant response, researchers are focused on improving the osseonintegration of implants by using pharmaceutical compounds, like bisphosphonates, as bioactive and osteoinductive coatings [ 1 , 2 , 4 , 25 , 26 , 27 , 28 , 29 ]. The bisphosphonates (BP) class of synthetic drugs is frequently used for the treatment of bone diseases; osteoporosis, bone cancer, osteopenia, and Paget’s disease [ 2 , 7 , 30 , 31 , 32 ].…”